Recombinant Rat CD19 Fc Chimera Protein, CF

• Reactivity: Rt
• Applications: Bioactivity
• Format: Carrier-Free

Recombinant Rat CD19 Fc Chimera Protein, CF Summary

• Details of Functionality: Measured by its binding ability in a functional ELISA. When Recombinant Rat CD19 Fc Chimera(Catalog # 10525-CD) is immobilized at 5 µg/mL,100 µL/well, recombinant biotinylated human CD81 Fc Chimera binds with an ED₅₀ of 10-60 μg/mL.
• Source: Chinese Hamster Ovary cell line, CHO-derived rat CD19 protein
  

  Rat CD19 (Arg19-Gly287) Accession # NP_001013255.2	IEGRMDP	Mouse IgG2a (Glu98-Lys330)
  N-terminus		C-terminus

• Accession #: NP_001013255.2
• N-terminal Sequence: Arg19
• Structure / Form: Disulfide-linked homodimer
• Protein/Peptide Type: Recombinant Proteins
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Endotoxin Note: <0.10 EU per 1 μg of the protein by the LAL method.

Applications/Dilutions

• Dilutions:
  • Bioactivity
• Theoretical MW: 57 kDa.
  Disclaimer note: The observed molecular weight of the protein may vary from the listed predicted molecular weight due to post translational modifications, post translation cleavages, relative charges, and other experimental factors.
• SDS-PAGE: 80-95 kDa, under reducing conditions

Packaging, Storage & Formulations

• Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
  • 12 months from date of receipt, -20 to -70 °C as supplied.
  • 1 month, 2 to 8 °C under sterile conditions after reconstitution.
  • 3 months, -20 to -70 °C under sterile conditions after reconstitution.
• Buffer: Lyophilized from a 0.2 μm filtered solution in PBS.
• Purity: >90%, by SDS-PAGE visualized with Silver Staining and quantitative densitometry by Coomassie® Blue Staining.
• Reconstitution Instructions: Reconstitute at 500 μg/mL in PBS.

Notes

This product is produced by and ships from R&D Systems, Inc., a Bio-Techne brand.

Alternate Names for Recombinant Rat CD19 Fc Chimera Protein, CF

• B4
• B-lymphocyte antigen CD19
• B-lymphocyte surface antigen B4
• CD19 antigen
• CD19 molecule
• CD19
• CVID3
• Differentiation antigen CD19
• Leu-12
• MGC12802
• T-cell surface antigen Leu-12

Background

CD19, also known as B4, is a transmembrane glycoprotein of the immunoglobulin superfamily that plays a central role in B cell activation and humoral immune responses (1, 2). CD19 consists of an extracellular domain (ECD) with two C2-type Ig-like domains, a transmembrane segment, and a cytoplasmic domain with nine tyrosine residues, 3 of which are critical for function (1,2). Within the mature ECD, rat CD19 shares 57% and 88% amino acid sequence identity with human and mouse CD19, respectively. CD19 is expressed throughout B cell development from pre‑B cells through mature B cells, and it is commonly used as a B cell lineage marker (1, 2). It is required for the responsiveness of mature B cell to antigen stimulation, germinal center development, and antibody affinity maturation (1, 2). CD19 associates with the B cell antigen receptor (BCR), CD81, CD38, CD21, CD22, and IFITM1/CD225/Leu-13 (1, 3). These associations enable CD19 to amplify B cell signaling and reduce the threshold for antigen stimulation through the BCR (1, 3). CD19 polymorphisms and up-regulation can lead to the development of autoimmunity by promoting autoantibody production (2). CD19+ target cells can be recognized and killed by T cells that express anti-CD19 chimeric antigen receptors (CARs) (4). This interaction has been shown to be beneficial in the treatment of various B-cell malignancies, such as leukemias and lymphomas (4, 5).

1. Wang, K. et al. (2012) Exp. Hematol Oncol. 1:36.
2. Del Nargo, C.J. et al. (2005) Immunol Res. 31:229.
3. Yu, F. et al. (2010) J Neurooncol. 103:187.
4. Kochenderfer, J. et al. (2015) J Clin Oncol. 33:540.
5. Lee, D. et al. (2015) Lancet. 385:517.

Bioinformatics

• Uniprot:
  • NP_001013255.2()